MALVERN, Pa. and NEW YORK, Nov. 7, 2012 /PRNewswire/ --Auxilium Pharmaceuticals, Inc. (AUXL), a specialty biopharmaceutical company, and Pfizer Inc. (PFE) are amending their collaboration agreement for the development, commercialization and supply of XIAPEX in the European Union (EU) and certain other European and Eurasian countries (the "Collaboration Agreement"). As a result of this amendment, the Collaboration Agreement will terminate no later than April 24, 2013. Prior to the mutual termination date, the parties will continue to perform all of their obligations as described in the Collaboration Agreement. After the termination date, rights to commercialize XIAPEX and responsibility for regulatory activities for XIAPEX in these countries will revert to Auxilium.
(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )
"Auxilium remains committed to addressing the unmet needs of adult Dupuytren's contracture patients in the EU, and we now have the strategic flexibility to evaluate all of our options for the continuing commercialization of XIAPEX for the treatment of Dupuytren's contracture and for gaining approval for XIAPEX for the treatment of Peyronie's disease in the EU and other specified markets," said Adrian Adams, CEO and President of Auxilium. As a result of this mutual decision to conclude the collaboration, Auxilium will recognize $94 million of deferred revenue and $9 million of deferred costs in the fourth quarter of 2012.
"Pfizer is committed to working with Auxilium to ensure continuity of patient care during the transition period and effect a seamless transition," said Geno Germano, President and General Manager, Specialty Care and Oncology, Pfizer.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences. Auxilium markets Testim 1% (testosterone gel) for the topical treatment of hypogonadism and XIAFLEX (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord in the U.S. GSK co-promotes Testim with Auxilium in the U.S. Ferring International Center S.A. markets Testim in certain countries of the EU and Paladin Labs Inc. markets Testim in Canada. Pfizer has marketing rights for XIAPEX (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia through April 24, 2013; Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico. The sBLA for XIAFLEX for the treatment of Peyronie's disease was submitted to the FDA on November 7, 2012. Additionally, collagenase clostridium histolyticum ("CCH") is in phase IIa of development for the treatment of Frozen Shoulder syndrome (adhesive capsulitis) and phase Ib of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue additional indications for CCH. For additional information, visit http://www.auxilium.com.
About Pfizer Inc.
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at http://www.pfizer.com.
AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the expected termination of the Company's collaboration agreement with Pfizer and the Company's plans for development and commercialization of XIAPEX in the EU and certain other European and Eurasian countries; and products in development for Peyronie's disease, Frozen Shoulder syndrome and cellulite. Forward-looking statements often address Auxilium's expected future financial position or business strategy and plans and objectives of management for future operations. Forward-looking statements provide Auxilium's current expectations or forecasts of future events. Auxilium's performance and financial results could differ materially from those reflected in these forward-looking statements due to various risks and uncertainties. A more detailed list and description of the risks and uncertainties that Auxilium faces may be found under the heading "Risk Factors" in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, which are on file with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of the forward-looking statements contained in this release may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Auxilium undertakes no obligation to update publicly any forward-looking statement.
Continue reading here:
Auxilium and Pfizer Will Conclude Agreement on XIAPEX® EU Collaboration
- Female Hypogonadism Symptoms | eHow - May 18th, 2021
- Low T - My life was falling apart because I had low testosterone - April 25th, 2021
- Hypogonadism - April 11th, 2021
- Testosterone cream and gel for supplementation treating hypogonadism - March 13th, 2021
- Testosterone Treatments May Alleviate Negative Effects of Type-Two Diabetes - December 8th, 2020
- More than 152 Million Men Suffer from Hypogonadism and Low Testosterone - November 26th, 2020
- Clomiphene Citrate for Low-T - October 28th, 2020
- NATESTO (testosterone) Nasal Spray - October 27th, 2020
- Risk Factors for and Causes of Male Hypogonadism - October 11th, 2020
- What Is Male Hypogonadism - August 14th, 2020
- Excessive Use of Tylenol / Acetaminophen May Negatively Affect Testosterone Levels in Unborn Boys - August 1st, 2020
- Ordering Testosterone Replacement Therapy (TRT) – Buy it Online! - May 8th, 2020
- Hypogonadism: Treatment, Diagnosis, and Prognosis - April 16th, 2020
- Testosterone Replacement Beneficial for Modern Men? - February 11th, 2020
- HIV and Testosterone Deficiency - verywell.com - July 17th, 2016
- Hypogonadism - UT Medical Center - July 17th, 2016
- Hypogonadism - Definition, Causes, Symptoms and Treatment - July 17th, 2016
- Lipocine - Hypogonadism - July 17th, 2016
- Hypogonadism - Risks, Symptoms and Leading Causes | Treato - July 17th, 2016
- Hypogonadism and Hypogonadism Resources - What is ... - July 17th, 2016
- Male Hypogonadism - Genitourinary Disorders - Merck ... - July 9th, 2016
- Male - Hypogonadism -- Low T Treatment Help!? - Drugs.com - May 6th, 2016
- Hypogonadism Causes Infertility. Learn how to detect and ... - May 6th, 2016
- BodyLogicMD - Hypogonadism (Low Testosterone in Men) - February 8th, 2016
- Hypogonadism | Disorders | Knowledge Base - August 26th, 2015
- hypogonadism | pathology | Britannica.com - July 22nd, 2015
- Male hypogonadism Tests and diagnosis - Mayo Clinic - May 23rd, 2015
- Hypogonadism (Medical Condition) - Video - April 21st, 2015
- Treatment Options for Hypogonadism - Healthline - April 4th, 2015
- Hypergonadotropic hypogonadism - Wikipedia, the free ... - March 23rd, 2015
- Testosterone treatment of male hypogonadism - UpToDate - March 23rd, 2015
- Statins may lower testosterone and libido - March 16th, 2015
- Hypogonadotropic Hypogonadism - Pipeline Review, H1 2015 - March 13th, 2015
- Biomarker monitors testosterone therapy for osteoporosis - March 12th, 2015
- The effect of hypogonadism and testosterone-enhancing therapy - Video - March 5th, 2015
- Causes of secondary hypogonadism in males - March 2nd, 2015
- Male hypogonadism: symptoms, cause, treatment, risk ... - February 18th, 2015
- Male Hypogonadism 1/28/15 - Video - January 31st, 2015
- What is Hypogonadism - Symptoms and Treatment | Hormone ... - January 30th, 2015
- Auxilium Announces Results from Special Meeting of Stockholders - January 28th, 2015
- Male hypogonadism pathophysiology - Video - January 14th, 2015
- Endo to Acquire Rights to Testosterone Nasal Gel Natesto - Analyst Blog - November 26th, 2014
- Testosterone Deficiency (Hypogonadism) Overview ... - November 23rd, 2014
- Male Hypogonadism Therapeutic Pipeline Industry Review, H2 2014 - Video - November 7th, 2014
- Hypogonadism in men living with HIV - Video - November 7th, 2014
- Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog - November 5th, 2014
- Urology Care Foundation - Urology A-Z - Low Testosterone - November 3rd, 2014
- Male Hypogonadism: Male Reproductive Endocrinology: Merck ... - October 28th, 2014
- Hypogonadism Wikipedia - October 28th, 2014
- Hypogonadism No Moustache! No Beard!! - October 28th, 2014
- Apricus expands development pipeline with the in-licensing of US rights for fispemifene, a phase 2b ready asset, from ... - October 21st, 2014
- Apricus expands development pipeline with in-licensing of US rights for fispemifene - October 21st, 2014
- The Wall Street Journal: Repros Therapeutics shares drop on drug application setback - October 18th, 2014
- Repros Therapeutics Analyst Brief Report; Androxal(R) Achieves Superiority in Top Line Analysis by Small Cap Street ... - September 30th, 2014
- Repros Reports Encouraging Late-Stage Data on Androxal - Analyst Blog - August 28th, 2014
- Repros Therapeutics Q2 Loss a Penny Wider than Expected - Analyst Blog - August 12th, 2014
- Prevalence, Diagnosis and Treatment of Hypogonadism in ... - April 30th, 2014
- Repros Completes Enrollment for Androxal Study - Analyst Blog - April 16th, 2014
- VLog #127 Frances Explains Hypogonadism. - Video - April 7th, 2014
- Hypogonadism: Types, Causes, & Symptoms - Medical ... - April 6th, 2014
- Male hypogonadism Symptoms - Diseases and Conditions ... - April 2nd, 2014
- Update on Endo's Product Portfolio - Analyst Blog - March 11th, 2014
- Unit Project 1 Hypogonadotropic hypogonadism - Video - March 8th, 2014
- Endo: FDA Oks AVEED Injection For Treatment Of Adult Men With Hypogonadism - March 6th, 2014
- Hypogonadism | Medscape - Latest Medical News, Clinical ... - February 23rd, 2014
- Hypogonadism : Types, Causes, & Symptoms - Healthline - February 17th, 2014
- Low Testosterone (Hypogonadism) in Men - Video - February 14th, 2014
- Hypogonadism: Types, Causes, & Symptoms Healthline - February 14th, 2014
- Testosterone Therapy Not Always Good for Older Men - February 11th, 2014
- Endocrine Society calls for large-scale studies to evaluate testosterone therapy risks - February 8th, 2014
- Study Finds Potential Heart Risks from Testosterone Therapy - February 3rd, 2014
- Hypogonadism - SharedJourney - January 23rd, 2014
- Hypogonadism | Medscape - Latest Medical News, Clinical Trials ... - December 30th, 2013
- Hypogonadism - HealthCentral - December 24th, 2013
- Hypogonadism - December 23rd, 2013
- Hypogonadism - Medscape Reference - December 21st, 2013
- Audio-Digest Foundation Announces the Release of Oncology Volume 04, Issue 16: Highlights from Future Directions ... - December 15th, 2013
- Male hypogonadism: Symptoms - MayoClinic.com - December 12th, 2013
- Exciting medical advances using HRT - December 12th, 2013
- Hypogonadism - About.com Men's Health - December 2nd, 2013
Word Count: 846